Athenex provides update from fda type a meeting regarding oral paclitaxel + encequidar in metastatic breast cancer

Buffalo, n.y., oct. 11, 2021 (globe newswire) -- athenex (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently held a type a meeting with the u.s. food and drug administration (fda) regarding the new drug application (nda) for oral paclitaxel and encequidar (oral paclitaxel) in metastatic breast cancer (mbc). the purpose of the meeting was to review with the fda a proposed design for a new clinical trial intended to address the deficiencies raised in the complete response letter received in february 2021 and discuss the potential regulatory path forward for oral paclitaxel in mbc in the u.s.
ATNX Ratings Summary
ATNX Quant Ranking